Overview

A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus

Status:
Not yet recruiting
Trial end date:
2023-10-11
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety of a study drug known as LY3209590 in Chinese participants with type 2 diabetes mellitus who are on a stable dose of basal insulin. Side effects and tolerability will be documented. Blood samples will be taken to assess how the body processes the study drug and the effect of the study drug on blood sugar levels. The study will last up to 18 weeks and may include 18 visits for each participant.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin Glargine